Response to: “Commentary on: phosphodiesterase type 5 inhibitors do not prevent curvature progression but shorten pain duration in the active phase of Peyronie’s disease
Research output: Contribution to journal › Comment/debate › Research › peer-review
We appreciate the commentary by Manfredi et al. on our study investigating the impact of phosphodiesterase type 5 inhibitors (PDE5is) on Peyronie’s disease (PD) in the active phase [1]. The attention devoted to non-surgical interventions in PD in recent years highlights a growing recognition of the need for effective non-invasive treatments for this condition. This increased focus may reflect a broader shift in medical practice towards holistic patient care, emphasizing options beyond surgical intervention. Despite the paucity of clinical studies, PDE5is hold promise as a viable, safe, and practical approach to managing the condition, potentially offering relief and influencing its progression [2, 3]. With their generally well-tolerated nature and favorable safety profile [4], PDE5is emerge as an appealing choice for PD management
Translated title of the contribution | a retrospective cohort study” |
---|---|
Original language | English |
Journal | International Journal of Impotence Research |
Volume | 36 |
Issue number | 3 |
Pages (from-to) | 297-298 |
ISSN | 0955-9930 |
DOIs |
|
Publication status | Published - 2024 |
ID: 388780058